Enfortumab Vedotin
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Urothelial Cancer
Conditions
Urothelial Cancer
Trial Timeline
Nov 1, 2023 → Jul 31, 2027
NCT ID
NCT06011954About Enfortumab Vedotin
Enfortumab Vedotin is a pre-clinical stage product being developed by Astellas Pharma for Urothelial Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06011954. Target conditions include Urothelial Cancer.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07139977 | Phase 2 | Recruiting |
| NCT07347314 | Phase 2 | Recruiting |
| NCT06862219 | Approved | Recruiting |
| NCT06891560 | Phase 2 | Recruiting |
| NCT06553885 | Phase 2 | Recruiting |
| NCT06394570 | Phase 1/2 | Recruiting |
| NCT06011954 | Pre-clinical | Recruiting |
| NCT05868265 | Phase 2 | Recruiting |
| NCT04754191 | Phase 2 | Active |
| NCT05014139 | Phase 1 | Terminated |
| NCT04995419 | Phase 2 | Completed |
| NCT03219333 | Phase 2 | Completed |
| NCT03070990 | Phase 1 | Completed |
| NCT02091999 | Phase 1 | Completed |
Competing Products
20 competing products in Urothelial Cancer